138 related articles for article (PubMed ID: 21417957)
1. Safety review of combination drugs for hyperlipidemia.
Farnier M
Expert Opin Drug Saf; 2011 May; 10(3):363-71. PubMed ID: 21417957
[TBL] [Abstract][Full Text] [Related]
2. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
3. Role of colesevelam in combination lipid-lowering therapy.
Jones MR; Nwose OM
Am J Cardiovasc Drugs; 2013 Oct; 13(5):315-23. PubMed ID: 23913404
[TBL] [Abstract][Full Text] [Related]
4. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
Sharma M; Ansari MT; Abou-Setta AM; Soares-Weiser K; Ooi TC; Sears M; Yazdi F; Tsertsvadze A; Moher D
Ann Intern Med; 2009 Nov; 151(9):622-30. PubMed ID: 19884623
[TBL] [Abstract][Full Text] [Related]
5. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
Goumas GS
Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of statin and fibrate combination therapy in lipid management.
Kota SK; Meher LK; Rao ES; Jammula S; Modi KD
Diabetes Metab Syndr; 2012; 6(3):173-4. PubMed ID: 23158983
[TBL] [Abstract][Full Text] [Related]
7. LDL reduction: how low should we go and is it safe?
Robinson JG
Curr Cardiol Rep; 2008 Nov; 10(6):481-7. PubMed ID: 18950559
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
10. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
11. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
12. Strategies to overcome statin intolerance.
Agouridis AP; Nair DR; Mikhailidis DP
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
[TBL] [Abstract][Full Text] [Related]
13. The power of statins: aggressive lipid lowering.
Jones PH
Postgrad Med; 2002 Oct; 112(4 Suppl):23-30. PubMed ID: 19667597
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
16. Dyslipidemia treatment: current considerations and unmet needs.
Malik S; Kashyap ML
Expert Rev Cardiovasc Ther; 2003 May; 1(1):121-34. PubMed ID: 15030302
[TBL] [Abstract][Full Text] [Related]
17. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
19. Safety of aggressive lipid management.
Davidson MH; Robinson JG
J Am Coll Cardiol; 2007 May; 49(17):1753-62. PubMed ID: 17466224
[TBL] [Abstract][Full Text] [Related]
20. Combining niacin with statins: does it help heart health?
Johns Hopkins Med Lett Health After 50; 2011 Dec; 23(10):1-2. PubMed ID: 22216465
[No Abstract] [Full Text] [Related]
[Next] [New Search]
